EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Oligometastatic RCC: Challenges and Emerging Therapeutic Strategies

Calliope Stavrou iD, Monica Thet, Kieran Sandhu, Shankar Siva iD, Cristian Udovicich iD, Nathan Lawrentschuk iD, Marlon Perera

Cancers · 16.06.2026 · 18 (12) · 1956

DOI: 10.3390/cancers18121956 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Cancers, online erschienen am 16.06.2026. Verfasst von Calliope Stavrou und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Royal Melbourne Hospital, Melbourne, VIC 3050, Australia. Die Arbeit nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background/objectives: Renal-cell carcinoma (RCC) accounts for approximately 4% of all solid tumours worldwide. Oligometastatic RCC, frequently defined as the presence of fewer than five metastatic lesions, is increasingly recognised as a clinically and prognostically distinct disease state, yet standardised treatment algorithms remain lacking.

Method

This narrative review summarises current local and systemic treatment strategies for oligometastatic RCC and identifies patient populations most likely to benefit based on 26 studies published within the past ten years.

Results

Stereotactic ablative radiotherapy (SABR) was the most frequently evaluated local modality, consistently demonstrating high local control rates with favourable toxicity profiles. Systemic therapies showed mixed efficacy and greater treatment-related adverse events, while evidence for radiofrequency ablation, cryoablation, and metastasectomy remains limited but suggests feasibility in selected patients.

Conclusions

Overall, current evidence supports local therapy—particularly SABR—in appropriately selected patients with oligometastatic RCC, though most available evidence is retrospective and concentrated in favourable-risk ccRCC populations, limiting generalizability. Further prospective research is needed to refine patient selection criteria and optimise treatment sequencing.

Schlagwörter

Stichwörter der Autor:innen

metastasis-directed therapyoligometastatic diseaserenal-cell carcinomastereotactic ablative body radiotherapy

Autor:innen und Institutionen

  • Department of Urology, Royal Melbourne Hospital, Melbourne, VIC 3050, Australia.
  • Peter MacCallum Cancer Centre, Melbourne, VIC 3000, Australia.
  • University of Cambridge, Cambridge CB2 1TN, UK.
  • Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, VIC 3010, Australia.
  • Department of Radiation Oncology, GenesisCare, Melbourne, VIC 3065, Australia.
  • Department of Surgery, University of Melbourne, Parkville, VIC 3010, Australia.

ORCID-Profile: Calliope Stavrou, Shankar Siva, Cristian Udovicich, Nathan Lawrentschuk

Zitieren

APA

Stavrou, C., Thet, M., Sandhu, K., Siva, S., Udovicich, C., Lawrentschuk, N., & Perera, M. (2026). Oligometastatic RCC: Challenges and Emerging Therapeutic Strategies. Cancers, 18(12), 1956. https://doi.org/10.3390/cancers18121956

Vancouver

Stavrou C, Thet M, Sandhu K, Siva S, Udovicich C, Lawrentschuk N, et al. Oligometastatic RCC: Challenges and Emerging Therapeutic Strategies. Cancers. 2026;18(12):1956. doi:10.3390/cancers18121956

BibTeX
@article{Stavrou2026,
  author = {Stavrou, Calliope and Thet, Monica and Sandhu, Kieran and Siva, Shankar and Udovicich, Cristian and Lawrentschuk, Nathan and Perera, Marlon},
  title = {Oligometastatic RCC: Challenges and Emerging Therapeutic Strategies},
  journal = {Cancers},
  year = {2026},
  volume = {18},
  number = {12},
  pages = {1956},
  doi = {10.3390/cancers18121956}
}
Kostenlos starten →